These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

158 related items for PubMed ID: 2590999

  • 1. Effect of lonidamine on the cytotoxicity of four alkylating agents in vitro.
    Rosbe KW, Brann TW, Holden SA, Teicher BA, Frei E.
    Cancer Chemother Pharmacol; 1989; 25(1):32-6. PubMed ID: 2590999
    [Abstract] [Full Text] [Related]

  • 2. Lonidamine as a modulator of alkylating agent activity in vitro and in vivo.
    Teicher BA, Herman TS, Holden SA, Epelbaum R, Liu SD, Frei E.
    Cancer Res; 1991 Feb 01; 51(3):780-4. PubMed ID: 1988117
    [Abstract] [Full Text] [Related]

  • 3. Fluosol-DA/carbogen with lonidamine or pentoxifylline as modulators of alkylating agents in the FSaIIC fibrosarcoma.
    Teicher BA, Herman TS, Tanaka J, Dezube B, Pardee A, Frei E.
    Cancer Chemother Pharmacol; 1991 Feb 01; 28(1):45-50. PubMed ID: 1904012
    [Abstract] [Full Text] [Related]

  • 4. Etoposide with lonidamine or pentoxifylline as modulators of alkylating agent activity in vivo.
    Tanaka J, Teicher BA, Herman TS, Holden SA, Dezube B, Frei E.
    Int J Cancer; 1991 Jun 19; 48(4):631-7. PubMed ID: 2045206
    [Abstract] [Full Text] [Related]

  • 5. Combination of the minor groove-binder U73-975 or the intercalator mitoxantrone with antitumor alkylating agents in MCF-7 or MCF-7/CP cells.
    Ayash L, Korbut T, Herman TS, Teicher BA.
    Cancer Lett; 1991 Dec 09; 61(1):7-14. PubMed ID: 1764699
    [Abstract] [Full Text] [Related]

  • 6. Modulation of antitumor alkylating agents by novobiocin, topotecan, and lonidamine.
    Schwartz GN, Teicher BA, Eder JP, Korbut T, Holden SA, Ara G, Herman TS.
    Cancer Chemother Pharmacol; 1993 Dec 09; 32(6):455-62. PubMed ID: 8258194
    [Abstract] [Full Text] [Related]

  • 7. Preclinical studies and clinical correlation of the effect of alkylating dose.
    Frei E, Teicher BA, Holden SA, Cathcart KN, Wang YY.
    Cancer Res; 1988 Nov 15; 48(22):6417-23. PubMed ID: 3180059
    [Abstract] [Full Text] [Related]

  • 8. Development of alkylating agent-resistant human tumor cell lines.
    Teicher BA, Frei E.
    Cancer Chemother Pharmacol; 1988 Nov 15; 21(4):292-8. PubMed ID: 3370736
    [Abstract] [Full Text] [Related]

  • 9. Influence of schedule on alkylating agent cytotoxicity in vitro and in vivo.
    Teicher BA, Holden SA, Eder JP, Brann TW, Jones SM, Frei E.
    Cancer Res; 1989 Nov 01; 49(21):5994-8. PubMed ID: 2790813
    [Abstract] [Full Text] [Related]

  • 10. Efficacy of pentoxifylline as a modulator of alkylating agent activity in vitro and in vivo.
    Teicher BA, Holden SA, Herman TS, Epelbaum R, Pardee AB, Dezube B.
    Anticancer Res; 1991 Nov 01; 11(4):1555-60. PubMed ID: 1746913
    [Abstract] [Full Text] [Related]

  • 11. Modulation of alkylating agents by lonidamine in vivo.
    Teicher BA, Holden SA, Herman TS, Frei E.
    Semin Oncol; 1991 Apr 01; 18(2 Suppl 4):7-10. PubMed ID: 1903216
    [Abstract] [Full Text] [Related]

  • 12. Combination of etanidazole with cyclophosphamide and platinum complexes.
    Teicher BA, Herman TS, Shulman L, Bubley G, Coleman CN, Frei E.
    Cancer Chemother Pharmacol; 1991 Apr 01; 28(3):153-8. PubMed ID: 1830248
    [Abstract] [Full Text] [Related]

  • 13. Modulation by lonidamine on the combined activity of cisplatin and epidoxorubicin in human breast cancer cells.
    Silvestrini R, Gornati D, Zaffaroni N, Bearzatto A, De Marco C.
    Breast Cancer Res Treat; 1997 Jan 01; 42(2):103-12. PubMed ID: 9138599
    [Abstract] [Full Text] [Related]

  • 14. In vitro effect of lonidamine on the cytotoxicity of mitomycin C and BCNU in human colon adenocarcinoma cells.
    Villa R, Zaffaroni N, Orlandi L, Bearzatto A, Costa A, Silvestrini R.
    Eur J Cancer; 1994 Jan 01; 30A(10):1534-40. PubMed ID: 7833114
    [Abstract] [Full Text] [Related]

  • 15. Alkylating agents: in vitro studies of cross-resistance patterns in human cell lines.
    Teicher BA, Cucchi CA, Lee JB, Flatow JL, Rosowsky A, Frei E.
    Cancer Res; 1986 Sep 01; 46(9):4379-83. PubMed ID: 3731096
    [Abstract] [Full Text] [Related]

  • 16. Cytotoxic effects of topotecan combined with various anticancer agents in human cancer cell lines.
    Kaufmann SH, Peereboom D, Buckwalter CA, Svingen PA, Grochow LB, Donehower RC, Rowinsky EK.
    J Natl Cancer Inst; 1996 Jun 05; 88(11):734-41. PubMed ID: 8637027
    [Abstract] [Full Text] [Related]

  • 17. The effect of lonidamine alone and in combination with cisplatin on in vitro growth and viability of lung squamous cell carcinoma cell lines.
    Raaphorst GP, Ko D, Feeley MM, Danjoux CE, Maroun J, Evans WK.
    Anticancer Res; 1991 Jun 05; 11(1):41-7. PubMed ID: 2018379
    [Abstract] [Full Text] [Related]

  • 18. Influence of scheduling on two-drug combinations of alkylating agents in vivo.
    Teicher BA, Holden SA, Jones SM, Eder JP, Herman TS.
    Cancer Chemother Pharmacol; 1989 Jun 05; 25(3):161-6. PubMed ID: 2513139
    [Abstract] [Full Text] [Related]

  • 19. Effect of fluosol-DA/carbogen on etoposide/alkylating agent antitumor activity.
    Teicher BA, Bernal SD, Holden SA, Cathcart KN.
    Cancer Chemother Pharmacol; 1988 Jun 05; 21(4):281-5. PubMed ID: 3131032
    [Abstract] [Full Text] [Related]

  • 20. In vitro potentiation by lonidamine of the cytotoxic effect of adriamycin on primary and established breast cancer cell lines.
    Savini S, Zoli W, Nanni O, Volpi A, Frassineti GL, Magni E, Flamigni A, Amadori A, Amadori D.
    Breast Cancer Res Treat; 1992 Jun 05; 24(1):27-34. PubMed ID: 1463869
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.